Published in final edited form as:

Chirality. 2010 May 15; 22(5): 495–513. doi:10.1002/chir.20771.

Evaluation of Dalbavancin as chiral selector for HPLC and comparison with Teicoplanin based chiral stationary phases

XIAOTONG ZHANG¹, YE BAO¹, KE HUANG¹, KIMBER L. BARNETT-RUNDLETT², and DANIEL W. ARMSTRONG¹

¹Department of Chemistry and Biochemistry, University of Texas at Arlington, Arlington, Texas

²Pfizer, Inc. Groton, Connecticut

Abstract

Dalbavancin is a new compound of the macrocyclic glycopeptide family. It was covalently linked to 5µm silica particles by using two different binding chemistries. Approximately two hundred and fifty racemates including (A) heterocyclic compounds; (B) chiral acids; (C) chiral amines; (D) chiral alcohols; (E) chiral sulfoxides and sulfilimines; (F) amino acids and amino acid derivatives; and (G) other chiral compounds were tested on the two new chiral stationary phases (CSP) using three different mobile phases. As dalbavancin is structurally related to teicoplanin, the same set of chiral compounds was screened on two commercially available teicoplanin CSPs for comparison. The dalbavancin CSPs were able to separate some enantiomers that were not separated by the teicoplanin CSPs and also showed improved separations for many racemates. However, there were other compounds only separated or better separated on teicoplanin CSPs. Therefore, the dalbavancin CSPs are complementary to the teicoplanin CSPs.

Keywords

dalbavancin; teicoplanin; chiral stationary phases; HPLC; macrocyclic glycopeptides; racemates; enantiomeric separation

INTRODUCTION

Macrocyclic antibiotics were first introduced as a new class of chiral selectors for enantioseparations by HPLC and capillary electrophoresis in 1994[1]. The ANSA family (rifamycin B and SV)[2,3] and glycopeptides group (vancomycin, ristocetin and teicoplanin [4–8]) were demonstrated to have the most advantageous structures for enantiomeric separations. There are many structurally related oligophenolic glycopeptides belonging to the later group which have proven to be useful. Thus far, vancomycin, ristocetin, teicoplanin, A82846B[9], LY307599[10], avoparcin[11] and A40926[12] of the macrocyclic glycopeptide family, have been evaluated as chiral selectors. These chiral selectors can be further divided into two groups according to the number of fused rings in the aglycone part of their structure. In comparison, vancomycin types have a three ring aglycone, while the teicoplanin-type glycopeptides have one more ring in the aglycone which makes it “semirigid”. They all show great selectivity over a wide range of chiral molecules including amino acids, carboxylic acids and neutral compounds. Their excellent enantioselective

separation capability have been attributed to the richness of different functional groups in their structures such as aromatic rings with and without chloro-substituents, ionizable phenolic moieties, amino groups, amide groups, carboxylates and carbohydrate moieties. Therefore, many kinds of intermolecular interactions, such as π - π and dipole-dipole interactions, hydrophobic interactions and hydrogen bonding, can be involved in the chiral recognition via association with these functional groups.[13]

Although all the macrocyclic glycopeptides are within the same family of compounds, small changes in their structure can result in significant differences in their enantiorecognition abilities. For example, α -amino acids are better separated on the teicoplanin aglycone based CSP, that is produced by cleaving all the carbohydrate moieties from teicoplanin[14]. In the case of A40926, there are only a few small structural variations compared to teicoplanin. However, it is found that some compounds can only be separated or better separated on the HPLC chiral stationary phase based on A40926, while the teicoplanin column separates a larger total number of racemates[12].

Dalbavancin is a new semisynthetic lipoglycopeptide derived from A40926, a naturally occurring glycopeptide produced by actinomycete *Nonomuraea* species[15]. It has enhanced activity against gram-positive bacteria and unique pharmacokinetics compared with existing drugs in its class [16]. In this work, two CSPs were prepared by binding dalbavancin to two different 5- μ m spherical silica gels respectively as to mirror the synthesis and make up of the Chirobiotic T and T2 columns. They are designated as the D1 and D2. Their enantioseparation capabilities were evaluated with 250 pairs of enantiomers containing different functional groups. These analytes were also screened on the commercial teicoplanin CSPs (i.e. Chirobiotic T and Chirobiotic T2) for comparison. These two CSPs are designated as the T1 and T2.

MATERIALS AND METHODS

Materials

All the racemic analytes tested in this study were purchased from Sigma-Aldrich. All HPLC grade solvents were obtained from VWR (Bridgeport, NJ). HPLC grade Kromasil silica gel (particle size 5 μ m, pore size 100 Å, and surface area 310m²/g) was obtained from Akzo Nobel (EKA Chemicals, Bohus, Sweden). LiChrospher Si(100) silica gel (particle size 5 μ m, pore size 100 Å, and surface area 400 m²/g) was purchased from Merck (Darmstadt, Germany). All organosilane compounds were obtained from Silar Laboratories (Wilmington, NC). These include: (3-aminopropyl) dimethylethoxysilane, (3-aminopropyl) triethoxysilane, [2-(carbomethoxy) ethyl] trichlorosilane, [1-(carbomethoxy)ethyl] methylchlorosilane, (3-isocyanatopropyl) triethoxysilane, and (3-glycidoxypropyl) triethoxysilane. Dalbavancin was the generous gift of Pfizer(Washington, MO).

Methods

Preparation of the D1 CSP—One gram of dried Dalbavancin (0.53 mmol) was dissolved by 55 ml anhydrous DMF in a 250 ml 3-neck round flask with mechanical stirring. Then triethylamine (0.72 ml, 5.16 mmol) and 3-(triethoxysilyl)propyl isocyanate (0.865 ml, 3.50

mmol) were added into the solution at room temperature under argon protection. The solution was heated to 95°C for 5 h and cooled to 60°C. The dried Kromasil silica (3.50 g, 5µm, 100 Å) was added into the solution. The mixture was heated to 105°C over night and then cooled to room temperature and filtered. The CSP was washed by methanol, methanol/water (50/50, v/v), pure water, and methanol (50 ml for each solvent), and dried in oven at 100°C overnight. Elemental analysis showed it has 8.0% carbon loading.

Preparation of the D2 CSP—The D2 stationary phase was prepared as previously described for the teicoplanin CSP. Five gram of Lichrospher silica gel was first dried at 150°C under vacuum, and then it is heated in toluene to reflux to remove azeotropically all residual water. It is followed by adding 2.5 mL of (3-aminopropyl triethoxysilane) and the reaction mixture was heated to reflux for 4 h. The modified silica gel was filtered and washed with toluene, methanol and dichloromethane and dried at 90°C overnight. Elemental analysis showed the derivatized silica gel has 4.0% carbon loading. A 2.5 mL portion of 1,6-diisocyanatohexane (15 mmol) was added to an ice-bath-cooled slurry of 2.5 g of 3-aminopropyl- Lichrospher in 50 mL of anhydrous toluene. Next, the mixture was heated at 70°C for 2 h. After cooling, the supernatant toluene phase was removed under an argon atmosphere. The excess reactant was removed by dry toluene washing. A suspension of 1 g of Dalbavancin (0.53 mmol) in 100 mL of dry pyridine was added dropwise to the wet activated silica. Next, the mixture was heated at 70°C for 12 h with stirring under an argon atmosphere. After cooling, the Dalbavancin bonded silica was washed with 50 mL portions in the sequence pyridine, water, methanol, acetonitrile and dichloromethane. It was dried under vacuum. Elemental analysis showed it has 11.0% carbon loading (increased by 7.0%).

Chromatographic condition CSPs were slurry packed into 250*4.6 mm stainless steel columns at 600 bar. Evaluation of the columns was conducted on HP 1090 HPLC system with a DAD UV detector and autosampler. Detection wavelengths were selected at 220 nm, 230 nm and 254 nm. The injection volumes were 5µl. All sample concentrations were 1 mg/ml. Separations were carried out under isocratic conditions at flow rate of 1 mL/min at 21°C. The mobile phases were premixed and degassed under vacuum for 10 minutes. The column dead times were tested by injection of solution of 1,3,5-tri-tert-butylbenzene in 100% methanol.

RESULTS AND DISCUSSION

The structure of Dalbavancin

Dalbavancin is a second generation glycopeptide antibiotic molecule (see Fig. 2). The major difference between dalbavancin and teicoplanin are: (a) different phenyl rings are chloro-substituted (see ring 2 and 3, Figs. 1 & 2); (b) the β-D-N-acetyl-glucosamine unit of teicoplanin (see ring 5, Figs. 1 & 2) is replaced by a simple hydroxyl group; (c) the primary hydroxyl group of N-acyl-glucosamine unit of teicoplanin has been oxidized to a carboxylic acid, which can generate an anion; (d) the primary amine group on the aglycone portion of teicoplanin is a secondary amine substituted by methyl group; (e) the carboxylic group close to phenyl ring 7 is converted to an amide group connected with three methylene groups and it has a dimethylamino group at the end (in dalbavancin); and (f) dalbavancin has 10 carbons in the carbon chain of β-D-N-acyl-glucosamine while teicoplanin only has 9. The last

difference noted above is the least likely to affect enantioseparation since one more methylene group does not provide any additional interactions that are beneficial to chiral recognition. Previous studies by our group has shown that the teicoplanin carbohydrate units play an important role in chiral recognition in that it helps in the separation of non-amino acid compounds. However, they also decrease the separation of many α -amino acid enantiomers [14]. Thus, the elimination of the β -D-N-acetyl-glucosamine unit in dalbavancin can substantially affect its the enantioselectivity. The other changes made to carboxylic groups, hydroxyl group and amino groups can also contribute to differences in the enantioselectivity of dalbavancin relative to teicoplanin. Dalbavancin has one tertiary amine and secondary amine respectively, and one carboxylic group on the N-acyl-glucosamine (Figs. 1&2). Whereas teicoplanin has only one carboxylic group connected to the aglycone and one primary amino group. As amine and carboxylic acids group are ionizable in aqueous solution and can interact via electrostatic interactions with charged analytes, these changes could lead to different chiral recognition abilities especially in the reversed phase.

Chromatographic Evaluation

The four columns, D1, D2, T1 and T2 were evaluated in three mobile phase modes: the normal phase, polar organic, and reversed-phase modes. In the normal phase mode, a mixture of 20% ethanol and 80% heptane were used as mobile phase. In the polar organic mode, 100% methanol was evaluated. In the reversed phase mode, methanol and water were mixed at the ratio of 1 to 1, and 0.1% NH₄OAc was used as buffer to adjust to pH 4.2. In order to compare the behavior of the different CSPs, results presented were obtained with the same mobile phase compositions for all of the CSPs. However, these conditions are not necessarily optimal for all the enantiomeric separations. Better separations can be obtained in specific cases if the mobile phase compositions and organic modifiers are optimized. The elution order of amino acids is “L” before “D”. Other compounds for which standards are not available have not yet be determined.

Approximately 250 compounds were injected on these columns. These analytes include (A) heterocyclic compounds; (B) chiral acids; (C) chiral amines; (D) chiral alcohols; (E) chiral sulfoxides and sulfilimines; (F) amino acid and amino acid derivatives; and (G) other chiral compounds. To simplify the presentation, Table 1, Table 2 and Table 3 list only the chromatographic results obtained when an enantiomeric separation was achieved.

Comparison of CSPs in the normal phase mode

Table 1 lists the separations achieved on the four columns when used in the normal phase mode. The number of successful enantioseparations achieved on D1, D2, T1 and T2 is 16, 17, 17 and 15 respectively. Interestingly, D2 always gives much greater retention for most of the analytes than the other three columns. Conversely, D1 has the least retention for most compounds. In the case of 2-azabicyclo [2.2.1]-hept-5-en-3-one, the retention factor (*k*) on D2 is three times as great as it is on D1. According to elemental analysis results of the CSPs, the carbon loading of D2 is higher than D1 by 3%. This can be caused either by more chiral selector loading or more unreacted linkages. And both of these factors can contribute to longer retention of analytes. Also, the additional ureic group of the D2 linkage can interact with analytes and increase the retention time. However, longer retention does not necessarily

result in better resolution of racemates. Among the racemates that both D1 and D2 can separate, 6 are better separated on D2 and 4 are better separated on D1 according to the separation factors (α). The enantiomeric separations of 2,6-bis(4-isopropyl-2-oxazolin-2-yl)pyridine, DL-3,4-dihydroxyphenyl- α -propylacetamide, cis-4,5-diphenyl-2-oxazolidinone, phenyl vinyl sulfoxide were only achieved on the D1 CSP in the normal phase mode. While methyl trans-3-(4-methoxyphenyl) glycidate and 5-hydroxymethyl-2(5H)-furanone enantiomers were separated on the D2 CSP only. Thus, it is obvious that the binding chemistry not only affects the retention factors, but it also changes the enantioselectivity in some cases. The influences of the nonchiral spacers on chiral separation were first studied for β -cyclodextrin chiral stationary phases [17]. Other studies have been done by several research groups [4, 18–21]. It was found that different types of chiral selectors favor linkages with different nature and length. However, for macrocyclic glycopeptide chiral selectors, each binding method has its own advantages, and sometimes unique selectivities.

Teicoplanin based columns can separate five compounds which the dalbavancin based CSPs did not. 2-Carboxy- γ -phenyl- γ -butyrolactone was barely separated by T1 and T2. But its separation was greatly improved to baseline on the D2 CSP. Among the total 29 compounds separated by these four columns in the normal phase mode, nineteen compounds are better or only separated by the dalbavancin based CSPs. There are no obvious structural differences between the solutes separated by one CSP versus another CSP. Representative chromatograms of analytes separated on the macrocyclic glycopeptide CSPs are shown in Fig. 3.

Comparison of CSPs in the polar organic mode

Methanol is used as mobile phase for the polar organic mode because it can elute analytes faster than acetonitrile for teicoplanin type CSPs [4]. A total of 13, 17, 18 and 18 racemates have been separated on D1, D2, T1 and T2 respectively. These analytes include carboxylic acids, amine, alcohol and neutral compounds. The results are listed in Table 2 and representative chromatograms are shown in Fig. 4. According to the enantioselectivity factors, three enantiomers are best separated on the D1 CSP, including one that was separated only on this CSP, 12 solutes were best separated by the D2 CSP including 4 that were separated only on this stationary phase, ten racemates were best separated by the T1 column including 4 that were separated only by this CSP, ten analytes were best separated by the T2 CSP including 9 that were separated only by this CSP. There are five compounds can be separated by all of the four CSPs. All of them are neutral molecules containing a hetero-five-member-ring in the structure. For the compound 5-(4-hydroxyphenyl)-5-phenylhydantoin, both the D1 and D2 CSPs gave much higher enantioselectivities and resolutions than those of T1 and T2 CSPs. The enantioselectivity factors for D1 and D2 are 1.95 and 4.07 respectively, and their resolutions correspond to 2.5 and 7.0 respectively, which indicates the excellent chiral resolving capabilities of Dalbavancin. Interestingly, the separation results changed significantly if a small alteration is made to the analyte's structure. For example, the only structural difference between 5-(3-hydroxyphenyl)-5-phenylhydantoin and 5-(4-hydroxyphenyl)-5-phenylhydantoin is position of the phenolic group. However, the previous baseline separation (R_s 7.0) achieved on D2 for 5-(4-

hydroxyphenyl)-5-phenylhydantoin was downgraded to a partial separation (R_s 1.3) on D2 for 5-(3-hydroxyphenyl)-5-phenylhydantoin. The substantial decline in the enantiomeric selectivity and resolution indicates that the position of phenol group is very important for chiral recognition. Some of the compounds separated in the polar organic mode can also be separated in the normal phase mode. For example, enantiomers of 2-carbethoxy- γ -phenyl- γ -butyrolactone can be separated on all of the four CSPs and was baseline separated by D2. However, it was only partially separated on D2 in the polar organic mode (R_s 0.7). This is because the analyte does not retain long enough to interact with the chiral selectors in the polar organic mode.

Comparison of CSPs in the reversed phase mode

Previous studies have revealed that reversed phase separations are among the most successful for the glycopeptide CSPs. Clearly, dalbavancin and teicoplanin CSPs follow this trend (see Fig. 5). 54 racemates have been separated by these four columns together. The results are listed in Table 3. Twenty three racemic solutes can be separated on both dalbavancin and teicoplanin CSPs. This suggests that these two chiral selectors have somewhat analogous chiral recognition capabilities due to their similar structures. Fourteen racemates were only separated on the dalbavancin columns. This also demonstrates that these two classes of CSPs are complimentary to each other. Atrolactic acid hemihydrate was baseline separated by D1(α =1.82, R_s =2.4) and D2(α =5.05, R_s =4.9) CSPs, but it was not separated on either of the teicoplanin based columns. These differences in enantioselective Gibbs energy correspond to 0.3 kcal/mol for D1, 0.9 kcal/mol for D2 and 0 kcal/mol for T1 and T2. In this particular example, the dalbavancin columns are much more effective. Interestingly, many of the analytes that are only separated on dalbavancin based CSPs have a free carboxylic group in their structure, such as N-(α -methylbenzyl)phthalic acid monoamide, α -methoxyphenylacetic acid, 3-oxo-1-indancarboxylic acid, 2-phenoxypropionic acid, 2-phenylpropionic acid, beta-phenyllactic acid and 1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid hydrochloride. This improved enantioselectivity towards carboxylic acids may be partly attributed to the tertiary amino group coupled to dalbavancin via an amide linkage (Fig. 1). In aqueous solution at pH 4.2, this group is protonated and carries a positive charge. This cationic site can interact with deprotonated carboxylic anions through charge-charge interactions which is an important process in chiral recognition. In contrast, the teicoplanin based CSPs (i.e. T2) only separated one of the tested amino acids, DL- α -aminophenyl-acetic acid and one of the tested carboxylic acids, 2-(2-chlorophenoxy)-propionic acid (R_s =0.4). Although there is one cationic site on native teicoplanin, it can be converted to a carbamate group when bonded to silica gel. Thus, the teicoplanin chiral selector only has one anionic site after linked to silica gel. The poor enantioselectivity of teicoplanin to some of the carboxylic acids in this study should be partially due to the lack of cationic sites on the teicoplanin molecule.

CONCLUSION

Two dalbavancin based CSPs were made using two different linkages to silica gel. Their enantiomeric separation capabilities have been investigated by comparison of the separations achieved on Chirobiotic T and T2 commercial columns. The structural

differences in the chiral selectors and linkages between the four CSPs presented in this work do not make one superior to another. All of them can separate some racemic solutes that can not be separated by the other CSPs tested. It is as expected that they show similar enantiomeric separation abilities to many analytes since their structures are very closely related. However, dalbavancin based CSPs exhibits enhanced enantioselectivities to carboxylic acids, where the additional cationic site of the chiral selector may play an important role during the chiral recognition process. Thus, it is obvious that these four CSPs are complementary to one another. If a racemate is poorly separated on one CSP, it is possible the other related CSPs will produce an enhanced separation. This is the principal of complementary separation that was model for the class of chiral selectors. Future work will involve the detailed study of elution order of enantiomers and binding linkage effects on dalbavancin based CSPs.

References

1. Armstrong DW, Tang Y, Chen Si, Zhou Y, Bagwill C, Chen J. Macrocyclic Antibiotics as a New Class of Chiral Selectors for Liquid Chromatography. *Anal Chem.* 1994; 66(9):1473–84.
2. Armstrong DW, Rundlett K, Reid G. Use of a Macrocyclic Antibiotic, Rifamycin B, and Indirect Detection for the Resolution of Racemic Amino Alcohols by CE. *Anal Chem.* 1994; 66(10):1690–5. [PubMed: 8030783]
3. Rundlett K, Armstrong DW. Effect of Micelles and Mixed Micelles on Efficiency and Selectivity of Antibiotic-Based Capillary Electrophoretic Enantioseparations. *Anal Chem.* 1995; 67(13):2088–95. [PubMed: 8694248]
4. Armstrong DW, Liu Y, Ekborg-ott KH. A covalently bonded teicoplanin chiral stationary phase for HPLC enantioseparations. *Chirality.* 1995; (6):474–97.
5. Berthod A, Liu Y, Bagwill C, Armstrong DW. Facile liquid chromatographic enantioresolution of native amino acids and peptides using a teicoplanin chiral stationary phase. *J Chromatogr.* 1996; 731:123.
6. D'Acquarica I, Gasparini F, Misiti D, Vllani D, Carotti A, Cellamare S, Muck S. Direct chromatographic resolution of carnitine and O-acylcarnitine enantiomers on a teicoplanin-bonded chiral stationary phase. *J Chromatogr A.* 1999; 857:145. [PubMed: 10536833]
7. Cancelliere G, D'Acquarica I, Gasparini F, Misiti D, Villani C. Synthesis and applications of novel, highly efficient HPLC chiral stationary phases: a chiral dimension in drug research analysis. *Pharmaceutical Science and Technology Today.* 1999; 2:484. [PubMed: 10603466]
8. Armstrong DW, Gasper M, Rundlett K. Highly enantioselective capillary electrophoretic separations with dilute solutions of the macrocyclic antibiotic ristocetin A. *J Chromatogr.* 1995; 689:285–304.
9. Reilly J, Risley DS. The separation of enantiomers by counter current capillary electrophoresis using the macrocyclic antibiotic A82846B. *LC-GC.* 1998; 16:170–178.
10. Sharp VS, Risley DS, McCarthy S, Huff BE, Strege MA. Evaluation of a new macrocyclic antibiotic as a chiral selector for use in capillary electrophoresis. *J of Liquid Chromatography & Related Technologies.* 1997; 20:887–898.
11. Ekborg-Ott KH, Kullman JP, Wang X, Gahm K, He L, Armstrong DW. Evaluation of the macrocyclic antibiotic avoparcin as a new chiral selector for HPLC. *Chirality.* 1998; 10:627–660. [PubMed: 9757575]
12. Berthod A, Yu T, Kullman JP, Armstrong DW, Gasparini F, D'Acquarica I, Misiti D, Carotti A. Evaluation of the macrocyclic glycopeptide A-40,926 as a high-performance liquid chromatographic chiral selector and comparison with teicoplanin chiral stationary phase. *J of Chromatography, A.* 2000:113–129.
13. Berthod A. Chiral recognition mechanisms with macrocyclic glycopeptide selectors. *Chirality.* 2008; 21:167–175. [PubMed: 18698639]

14. Berthod A, Chen X, Kullman JP, Armstrong DW, Gasparrini F, D'Acquarica I, Villani C, Carotti A. Role of the Carbohydrate Moieties in Chiral Recognition on Teicoplanin-Based LC Stationary Phases. *Anal Chem.* 2000; 72:1767–1780. [PubMed: 10784140]
15. Guay DR. Dalbavancin: an investigational glycopeptide. *Expert review of anti-infective therapy.* 2004; 2:845–52. [PubMed: 15566329]
16. Anderson VR, Keating GM. Dalbavancin. *Drugs.* 2008; 68:639–648. [PubMed: 18370443]
17. Berthod A, Chang CD, Armstrong DW. β -Cyclodextrin chiral stationary phases for liquid chromatography. Effect of the spacer arm on chiral recognition. *Talanta.* 1993; 40:1367–1373. [PubMed: 18965792]
18. Franco P, Lammerhofer M, Klaus PM, Lindner W. Novel cinchona alkaloid carbamate C9-dimers as chiral anion-exchange type selectors for high-performance liquid chromatography. *J of Chrom A.* 2000; 869:111–127.
19. Hyun MH, Kim DH. Spacer length effect of a chiral stationary phase based on (+)-(18-Crown-6)-2,3,11,12-tetracarboxylic acid. *Chirality.* 2004; 16:294–301. [PubMed: 15069659]
20. Zhong Q, He L, Beesley TE, Trahanovsky WS, Sun P, Wang C, Armstrong DW. Optimization of the synthesis of 2,6-Dinitro-4-trifluoromethylphenyl ether substituted cyclodextrin bonded chiral stationary phases. *Chromatographia.* 2006; 64:147–155.
21. Thunberg L, Allenmark S, Griberg A, Ek F, Frejd T. Evaluation of two pairs of chiral stationary phases effects from the length of the achiral spacers. *Chirality.* 2004; 16:614–624. [PubMed: 15390085]

Fig. 1.
The structure of the macrocyclic glycopeptide dalbavancin

Fig. 2.
The structure of the macrocyclic glycopeptide teicoplanin

Fig. 3.
Representative chromatograms of two analytes on the T1 and D2 CSPs in the normal phase
mode: heptane/ethanol 80/20 v/v; flow rate 1 ml/min

Fig. 4. Representative chromatograms of two analytes on the T1 and D2 CSPs in the polar organic phase mode: 100% methanol; flow rate 1 ml/min

Fig. 5. Representative chromatograms of two analytes on the T2 and D2 CSPs in the reversed phase mode: 20 mM NH_4NO_3 Buffer/Methanol 1/1 v/v; flow rate 1 ml/min

Table 1

Chromatographic data for the normal phase resolution of racemic compounds on D1, D2, T1 and T2 columns

Compound name	Structure	CSPs	80% Heptane/20% Ethanol		
			k_1	α	R_s
2,6-Bis(4-isopropyl-2-oxazolin-2-yl)pyridine		D1	1.04	1.18	1.0
2-Carboethoxy-gamma-phenyl-gamma-butyrolactone		D1	1.34	1.13	0.9
		D2	2.90	1.35	1.5
		T1	1.47	1.03	0.5
		T2	1.15	1.07	0.5
5,5-dimethyl-4-phenyl-2-oxazolidinone		D1	3.93	1.38	1.4
		D2	10.72	1.57	1.8
		T2	4.19	1.44	1.4
N-(2,3-Epoxypropyl)-phthalimide		D2	2.28	1.12	0.9
		T1	1.99	1.07	1.0
Guaiacol glyceryl ether carbonate		T1	7.72	1.05	0.5
alpha-Methyl-alpha-phenyl-succinimide		D1	2.02	1.11	0.9
		D2	4.52	1.44	2.2
		T1	2.37	1.23	1.5
		T2	2.40	1.21	1.4

Compound name	Structure	CSPs	80% Heptane/20% Ethanol		
			k_1	α	R_s
2-Phenylglutaric anhydride		T1	3.27	1.06	0.5
Methyl trans-3-(4-methoxyphenyl) glycidate		D2	1.07	1.58	1.8
3-(alpha-Acetyl-4-chlorobenzyl)-4-hydroxycoumarin		D1 D2 T2	0.88 0.85 0.89	1.39 1.21 1.21	1.4 0.7 1.2
Warfarin		D1 D2 T2	0.83 1.91 0.89	1.44 1.17 1.17	1.5 0.8 1.0
2-Azabicyclo[2.2.1]-hept-5-en-3-one		D1 D2 T1	4.26 14.52 7.59	1.29 1.16 1.06	1.5 0.8 0.7
2-(3-chlorophenoxy)propionamide		D1 D2 T1 T2	1.49 2.97 2.21 2.18	1.13 1.36 1.09 1.12	1.0 2.2 1.2 1.3
DL-3,4-dihydroxyphenyl- α -propylacetamide		D1	7.43	1.07	0.6

Compound name	Structure	CSPs	80% Heptane/20% Ethanol		
			k_1	α	R_s
1,5-Dimethyl-2-pyrrolidinone		D2	2.62	1.26	1.3
		T1	3.31	1.03	1.4
alpha, alpha-Dimethyl-beta-methylsuccinimide		D1	1.05	1.33	1.5
		D2	2.10	1.51	2.5
		T1	1.69	1.10	1.4
		T2	1.55	1.16	1.3
1,5-Dimethyl-4-phenyl-2-imidazolidinone		D1	1.57	1.26	1.4
		D2	4.86	1.65	3.6
		T1	3.24	1.70	2.3
		T2	2.78	1.11	1.0
N,N'-Dibenzyl-tartramide		T1	6.41	1.04	0.5
2,2'-Diamino-1,1'-binaphthalene		D2	5.03	1.05	0.5
		T2	3.40	1.16	1.3
cis-4,5-Diphenyl-2-oxazolidinone		D1	4.52	1.66	2.6
2,3-Dihydro-7a-methyl-3-phenylpyrrolo[2,1-b]oxazol-5(7aH)-one		T1	2.29	1.04	0.8
		T2	1.90	1.05	0.5

Compound name	Structure	CSPs	80% Heptane/20% Ethanol		
			k_1	α	R_s
Ethyl 11-cyano-9,10-dihydro-endo-9,10-ethanoanthracene-11-carboxylate		D2	1.03	1.17	0.8
		T1	0.72	1.05	0.5
furoin		D1	2.61	1.04	1.0
		D2	6.45	1.28	1.3
		T1	3.28	1.22	2.3
		T2	3.88	1.20	1.8
Ftorafur		D1	7.58	1.33	1.4
		T1	15.90	1.17	0.9
Glycidyl trityl ether		T2	0.24	1.15	0.5
5-hydroxymethyl-2(5H)-furanone		D2	7.77	1.27	1.5
Phenyl vinyl sulfoxide		D1	1.41	1.09	0.8
Phensuximide		D2	2.55	1.12	0.9
		T1	2.28	1.11	1.4
		T2	2.13	1.22	1.6

Compound name	Structure	CSFs	80% Heptane/20% Ethanol		
			k_1	α	R_s
Ruelene		D2	0.79	1.09	0.5
		T2	0.66	1.71	1.2
3a,4,5,6-Tetrahydro-succininido[3,4-b]acenaphthen-10-one		D1	5.93	1.44	1.8
		T1	6.79	1.25	1.4
		T2	0.59	1.94	0.9

Table 2

Table 1. Chromatographic data for the polar organic phase resolution of racemic compounds on D1, D2, T1 and T2 columns

Compound name	Structure	CSPs	100% MeOH		
			k_1	α	R_s
Chlorthalidone		D2	0.44	1.28	0.7
2-Carboxy-gamma-phenyl-gamma-butyrolactone		D2	0.13	1.51	0.7
5,5-dimethyl-4-phenyl-2-oxazolidinone		D1 T2	0.22 0.13	1.38 2.03	1.0 1.4
alpha-Methyl-alpha-phenyl-succinimide		D2	0.23	1.30	0.7
(cis)-(±)-3,3a,8,8a-Tetrahydro-2H-indenol[1,2-d]oxazol-2-one		D1 D2 T1 T2	0.84 2.74 1.02 0.70	1.98 1.96 1.23 1.15	3.0 2.7 1.0 0.9
2-(4-Nitrophenyl)propionic acid		T2	0.17	1.35	0.7
4-Methyl-5-phenyl-2-oxazolidinone		D1 D2	0.26 0.53	2.36 4.24	2.5 5.5

Compound name	Structure	CSPs	100% MeOH		
			k_1	α	R_s
Alprenolol		T1	0.28	2.79	4.4
		T2	3.46	1.25	2.7
DL-alpha-Aminophenyl-acetic acid		T2	0.30	3.77	1.3
2-Azabicyclo[2.2.1]-hept-5-en-3-one		D1	0.24	1.20	0.8
		D2	0.61	1.19	0.9
Bamethane		T2	3.88	1.19	1.5
1,1'-Binaphthyl-2,2'-diylhydrogenphosphate		T1	0.21	1.87	3.2
4-Benzyl-2-oxazolidinone		D1	0.61	1.16	0.9
		D2	2.07	1.08	0.5
		T1	0.72	1.29	1.5
		T2	0.39	1.23	0.9
4-Benzyl-5, 5-dimethyl-2-oxazolidinone		D1	0.29	1.20	0.8
		D2	0.65	1.78	2.3
		T1	0.36	2.73	4.8
		T2	0.15	1.84	1.4

Compound name	Structure	CSPs	100% MeOH		
			k_1	α	R_s
DL-2-(2-Chlorophenoxy)-propionic acid		T2	0.04	3.85	1.3
cis-4,5-Diphenyl-2-oxazolidinone		D1 T1 T2	0.22 0.25 0.21	1.62 1.75 1.71	1.4 3.2 1.5
4-(Diphenylmethyl)-2-oxazolidinone		D1 D2 T1	0.38 1.08 0.41	1.45 1.47 1.55	1.2 1.5 1.6
2,2'-Diamino-1,1'-binaphthalene		T2	0.24	1.10	0.5
Florafur		D1 T1	0.29 0.50	1.20 1.08	0.8 0.6
Glycidyl trityl ether		T1	0.09	1.23	0.5
5-(4-hydroxyphenyl)-5-phenylhydantoin		D1 D2 T1 T2	0.51 2.59 0.36 0.68	1.95 4.07 1.08 1.44	2.5 7.0 0.5 1.4

Compound name	Structure	CSPs	100% MeOH		
			k_1	α	R_s
5-(3-hydroxyphenyl)-5-phenylhydantoin		D2	1.51	1.32	1.3
		T1	0.32	1.11	0.6
		T2	0.49	1.23	0.9
Hydrobenzoin		T1	0.09	1.22	0.5
DL-Homocysteine thiolactone hydrochloride		T2	3.06	1.19	1.8
4-Hydroxy-2-pyrrolidinone		D2	0.60	1.37	1.3
5-(Hydroxymethyl)-2-pyrrolidinone		D2	0.68	2.06	2.9
		T1	0.50	1.19	1.4
5-hydroxymethyl-2(5H)-furanone		D2	0.42	1.54	1.4
		T1	0.29	1.08	0.5
Iopanoic acid or(3-[3-Amino-2,4,6-triiodophenyl]-2-ethyl-propanoic acid		D1	0.26	1.23	0.9

Compound name	Structure	CSPs	100% MeOH		
			k_1	α	R_s
Methoxyphenamine		D2	0.50	1.78	2.2
		T1	0.31	1.27	1.2
		T2	0.34	1.23	0.8
Mephesisin		T1	0.09	1.32	0.6
Metanephine hydrochloride		T2	1.83	1.29	1.0
2-Phenoxypropionic acid		T2	0.02	6.80	1.2
5-Phenyl-2-(2-propynyl-amino)-2-oxazolin-4-one		D1	0.27	1.88	1.3
		D2	0.46	3.81	3.0
		T1	0.31	1.46	0.9
3a,4,5,6-Tetrahydro-succininido[3,4-b]acenaphthen-10-one		D1	0.30	1.14	0.7
		D2	0.81	1.24	0.9
		T1	0.31	1.16	1.0
		T2	0.33	1.19	0.7

Table 3

Chromatographic data for the reversed phase resolution of racemic compounds on D1, D2, T1 and T2 columns

Compound name	Structure	CSPs	NH ₄ OAc Buffer 50%/MeOH 50%		
			K ₁	A	R _s
Benzoin methyl ether		2	6.25	1.29	1.4
2,6-Bis(4-isopropyl-2-oxazolin-2-yl)pyridine		D2	1.74	1.58	2.3
		T2	0.79	1.94	3.0
Chlorthalidone		D2	1.86	1.41	1.3
		T1	0.45	1.12	0.8
		T2	0.93	1.06	0.5
2-Carboxy-gamma-phenyl-gamma-butyrolactone		D2	5.21	1.11	0.8
1,5-dimethyl-4-phenyl-2-imidazolidinone		D2	2.80	1.21	1.4
		T1	0.57	1.05	0.5
		T2	2.06	1.10	0.9
1,5-dimethyl-4-phenyl-2-imidazolidinone		D2	2.80	1.21	1.4
		T1	0.57	1.05	0.5
		T2	2.06	1.10	0.9

Compound name	Structure	CSPs	NH ₄ OAc Buffer 50%/MeOH 50%		
			K ₁	A	R _s
3,4-dihydroxyphenyl-2-propylacetamide		D2	2.19	0.90	0.6
2,3-Dibenzoyl-DL-tartaric acid		D2	3.01	1.10	0.5
5,5-dimethyl-4-phenyl-2-oxazolidinone		D1	0.75	1.84	1.2
5-Methoxy-1-indanone-3-acetic acid		D2	1.41	1.10	0.6
alpha-Methyl-alpha-phenyl-succinimide		D2 T1 T2	1.20 0.49 0.69	1.23 1.13 1.12	1.2 1.0 0.8
3,3a,8,8a-Tetrahydro-2H-indeno[1,2-d]oxazol-2-one		D1	1.52	1.61	1.5
(1-phenethyl)phthalimide		D2 T1 T2	4.81 0.89 2.38	1.10 1.07 1.06	0.8 0.8 0.5

Compound name	Structure	CSFs	NH ₄ OAc Buffer 50%/MeOH 50%			
			K ₁	A	R _s	
2-(4-Nitrophenyl)propionic acid		D1	1.29	1.30	1.4	
		D2	3.33	1.17	1.0	
Methyl trans-3-(4-methoxyphenyl)glycidate		D2	1.49	1.10	0.6	
DL-alpha-Aminophenyl-acetic acid		T2	0.50	5.05	4.6	
Atrolactic acid hemihydrate		D1	0.80	1.82	2.4	
		D2	0.59	5.05	4.9	
4-Benzyl-2-oxazolidinone		T1	8.50	1.03	0.9	
		T2	1.29	1.30	1.5	
(-/+)-4-Benzyl-5,5-dimethyl-2-oxazolidinone		D1	1.46	1.31	1.5	
		T1	1.00	3.57	5.9	
2-(2-Chlorophenoxy)-propionic acid		D1	1.00	1.42	1.2	
		D2	1.10	2.43	2.4	
		T2	0.04	0.62	0.4	

Compound name	Structure	CSFs	NH ₄ OAc Buffer 50%/MeOH 50%		
			K ₁	A	R _s
2-(4-chloro-2-methyl-phenoxy)propionic acid		D1	1.21	1.33	1.2
		D2	1.63	1.64	2.0
2-(3-chlorophenoxy)propionamide		D2	1.42	1.18	1.0
		T2	0.77	1.04	0.4
(±)Camphor p-tosyl hydrazon		T1	0.97	1.14	1.0
cis-4,5-Diphenyl-2-oxazolidinone		D1	1.63	1.23	1.3
		T1	0.87	1.42	2.9
		T2	1.94	1.44	2.7
4-(Diphenylmethyl)-2-oxazolidinone		D1	2.28	1.20	1.2
		T1	1.31	1.59	1.8
		T2	2.06	1.22	1.3
2,2'-Diamino-1,1'-binaphthalene		T1	1.01	1.11	1.0
1,5-Dimethyl-2-pyrrolidinone		D2	0.35	1.16	0.6

Compound name	Structure	CSPs	NH ₄ OAc Buffer 50%/MeOH 50%			
			K ₁	A	R _s	
alpha, alpha-Dimethyl-beta-methylsuccinimide		D2	0.37	1.52	1.4	
		T1	0.30	1.07	0.5	
		T2	0.29	1.14	0.6	
Europium tris[3-(trifluoromethylhydroxy methylene)]-(-) camphorate		D2	2.09	1.33	0.8	
Ethyl 11-cyano-9,10-dihydro-endo-9,10-ethanoanthracene-11-carboxylate		D2	4.66	1.04	0.5	
		T2	2.07	1.07	0.6	
furoin		D2	0.73	1.09	0.5	
		T2	0.42	1.07	0.4	
Ftorafur		T1	0.94	1.08	0.9	
DL-Homocysteine thiolactone hydrochloride		D2	0.67	1.15	0.8	
		T2	1.40	1.04	0.5	

Compound name	Structure	CSPs	NH ₄ OAc Buffer 50%/MeOH 50%			
			K ₁	A	R _s	
5-(Hydroxymethyl)-2-pyrrolidinone		D2	0.24	1.99	1.4	
5-hydroxymethyl-2(5H)-furanone		D2	0.31	1.79	1.4	
		T2	0.15	1.20	0.5	
5-(4-hydroxyphenyl)-5-phenylhydantoin		D1	3.00	1.48	1.8	
		T1	1.27	1.17	1.2	
5-(3-hydroxyphenyl)-5-phenylhydantoin		D1	2.36	1.18	1.2	
		T1	1.15	1.15	1.2	
		T2	4.11	1.36	1.5	
Iopanoic acid or(3-[3-Amino-2,4,6-triiodophenyl]-2-ethyl-propanoic acid		D1	1.94	1.16	0.9	
4-Isobutyl-alpha-methylphenylacetic acid		D1	1.91	1.08	0.7	
(±)2,3-O-Isopropylidene 2,3-dihydroxy-1,4-bis(di-phenylphosphino)butane		D2	4.67	1.21	1.0	

Compound name	Structure	CSPs	NH ₄ OAc Buffer 50%/MeOH 50%		
			K ₁	A	R _s
Methoxyphenamine		D2	1.68	2.00	1.2
		T2	9.30	1.03	0.4
N-(alpha-Methylbenzyl)phthalic acid monoamide		D1	0.71	1.66	2.0
alpha-Methoxyphenylacetic acid		D1	0.66	1.07	0.5
3-Oxo-1-indancarboxylic acid		D2	1.64	1.50	1.5
2-Phenoxypropionic acid		D2	0.57	2.73	3.3
2-Phenylpropionic acid		D2	1.10	1.10	0.5

Compound name	Structure	CSPs	NH ₄ OAc Buffer 50%/MeOH 50%		
			K ₁	A	R _s
5-Phenyl-2-(2-propynyl-amino)-2-oxazolin-4-one		D1	0.86	1.69	1.5
Phenyl vinyl sulfoxide		D2	1.08	1.25	1.3
		T1	0.52	1.13	1.0
		T2	0.56	1.27	1.4
DL-beta-Phenyllactic acid		D1	0.41	1.14	0.6
(±)-5-(alpha-Phenethyl)semioxamazide		D2	0.70	1.07	0.5
		T2	0.50	1.13	0.7
Phensuximide		D2	1.01	1.31	1.4
		T2	1.00	1.31	1.4
1,2,3,4-Tetrahydro-3-isoquinolinecarboxylic acid hydrochloride		D1	0.73	1.65	1.5
Terbutaline hemisulfate salt		T2	5.63	1.22	3.1

Compound name	Structure	CSPs	NH ₄ OAc Buffer 50%/MeOH 50%		
			<i>K</i> ₁	<i>A</i>	<i>R</i> _s
3a,4,5,6-Tetrahydro-succininidol[3,4-b]acenaphthen-10-one		D1	1.06	1.30	1.2
		T1	0.93	1.42	5.0